Feng Ren

Feng Ren is currently the co-CEO, CSO, and Head of Drug R&D at Insilico Medicine. Prior to this, Feng Ren held various positions at 上海美迪西生物医药股份有限公司 from 2018 to 2021 and at GSK R&D China from 2007 to 2018. Feng Ren has a Ph.D. in Organic Chemistry from Harvard University, an M.Sc. in Inorganic Chemistry from the National University of Singapore, and a B.E. in Polymer Physics from the University of Science and Technology of China. Throughout their career, Feng Ren has been actively involved in the discovery of small molecules for neuroinflammation/neurodegeneration diseases and has successfully led cross-functional program teams in drug research and development.